Ads
related to: new treatments for postherpetic neuralgiaconsumereview.org has been visited by 100K+ users in the past month
pain.com has been visited by 10K+ users in the past month
Search results
Results From The WOW.Com Content Network
Postherpetic neuralgia (PHN) is neuropathic pain that occurs due to damage to a peripheral nerve caused by the reactivation of the varicella zoster virus (herpes zoster, also known as shingles). PHN is defined as pain in a dermatomal distribution that lasts for at least 90 days after an outbreak of herpes zoster. [ 1 ]
EMA401 is a drug under development for the treatment of peripheral neuropathic pain.Trials were discontinued in 2015, with new trials scheduled to begin March, 2018. [1] It was initially established as a potential drug option for patients suffering pain caused by postherpetic neuralgia. [2]
Higher doses were associated with a greater response to treatment. [8] [10] [9] A Phase II trial meant to assess the safety and efficacy of retigabine for treating postherpetic neuralgia was completed in 2009, but failed to meet its primary endpoint. Preliminary results were reported by Valeant as "inconclusive". [19]
Neuropathic pain and post-herpetic neuralgia can commonly persist for more than 3 months and a year to 18 months is not uncommon. More than 50% of patients report experiencing post-herpetic neuralgia. [2] Post-herpetic fatigue is also a common long term side effect and may persist for several months to a year or more.
Zoster vaccination is used to prevent shingles and its complications, including postherpetic neuralgia. [8] [9] It can be considered a therapeutic vaccine, given that it is used to treat a latent virus that has remained dormant in cells since chicken pox infection earlier in life. [8]
New Prosthetics Restore Natural Movement Via Nerve Connection The Amp Fitness machine is a groundbreaking $1,795 home gym powered by advanced artificial intelligence that transforms strength training.
Ad
related to: new treatments for postherpetic neuralgia